Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Investor Presentation (June 2023)
18 slides from Rhythm Biosciences's investor presentation, Jun 20, 2023
Slide 1: Investor Presentation
Investor Presentation A transformative and predictive cancer diagnostics technology company 20 June 2023 ASX:RHY
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undert
Slide 3: Introduction
Introduction • Rhythm’s initial product, ColoSTAT® is a simple, affordable blood test for the early detection of colorectal cancer for global mass-market screening • Developing alternative screening solutions for specific cancers via patient friendly blood tests is our primary focus • IP protection
Slide 4: Company Overview
Company Overview Capital Structure Share Price Chart ASX Code RHY Share Price (at 16 June 2023) $0.485 Shares on Issue 219.8 M Unlisted Options 17.2 M Market Capitalisation $115 M Cash in bank (31 March 2023) $6.8M Top 20 Shareholders 41% Board and Management Otto Buttula Trevor Lockett Lou Panaccio
Slide 5: ColoSTAT - Our Market Opportunity
ColoSTAT® - “Our Market Opportunity” Addressable market in the screening population – 481 million – currently low participation rates A simple blood test as an alternative to current Colorectal Cancer (CRC) screening methods Clinical trial performance at 81% Sensitivity. / 91% Specificity Internatio
Slide 6: Burden of Colorectal Cancer
BURDEN OF COLORECTAL CANCER Colorectal cancer (CRC) is treatable and often curable, yet is the second leading cause of cancer death globally CRC is a progressive disease in which epithelial cells in the colon or rectum grow out of control2 Global burden in 2020: 1.93 million new cases and ~940,000 d
Slide 7: Participation in CRC screening remains suboptimal despite national programmes
Participation in CRC screening remains suboptimal despite national programmes being in place in many countries worldwide Market Population Age – Screening Screening Screening Unscreened Incidence % of Total Population Method Participation Population/ of CRC Addressable Rate Opportunity Markets FIT,
Slide 8: Blood tests, such as ColoSTAT, are preferred by patients over FIT
Blood tests, such as ColoSTAT®, are preferred by patients over FIT as they provide a more acceptable way to participate in testing Blood-based tests are preferred over faecal tests (FIT) by 78–93% of people who are offered CRC testing1-5, with ease and convenience being the main reasons for their pr
Slide 9: ColoSTAT is a simple patient-friendly process compared with FIT
ColoSTAT® is a simple patient-friendly process compared with FIT CURRENT MARKET SCREENING PROCESS RHYTHM PROPOSED MARKET SCREEN PROCESS Faecal Immunochemical Test (FIT) Rhythm ColoSTAT® 1 Test-Kit mailed to eligible person SIMPLE 1 Visit GP/Clinic for blood test SIMPLE 2 Collect stool sample 2 Sampl
Slide 10: ColoSTAT Performance
ColoSTAT® Performance ColoSTAT® is expected to increase participation, leading to earlier detection and avoiding costly treatments ColoSTAT® Sensitivity Performance Comparison 85% • Accurate 80% ColoSTAT® obtains a qualitative likelihood of CRC presence based on 5 protein biomarker levels in the blo
Slide 11: Feedback about ColoSTAT
Feedback about ColoSTAT® A recent Advisory Board with clinicians and payers from the UK and Australia agreed that: 1 ColoSTAT® can be used as an alternative to the current screening methods 2 ColoSTAT® will increase screening participation rates ColoSTAT® may be able to reduce the burden of colonosc
Slide 12: Blood Based Test - Competitor Landscape
Blood Based Test - Competitor Landscape Price All converted to USD as of rate at 31/03/23 (ColoSTAT® $TBC) Galleri $949 Shield* $895 ColonSentry $795 SimpliPro Colon $448 Colox $430 Average Cost BeScreened $349 $453 USD Somatic Mutation CRC Solid Tissue $268 Colon Cancer Predictive Test (FAP) $201 C
Slide 13: Strategic Pillars and Direction
Strategic Pillars and Direction DISRUPTIVE TECHNOLOGY ✓ Provides an alternative to current screening methods through a well- established ELISA based technology GLOBAL CAPABILITY ✓ Manufacturing capability for our target markets ✓ Increase production capacity with further international and local CMOs
Slide 14: Platform Technology Expansion
Platform Technology Expansion Leveraging Rhythm’s own lead biomarker(s): Cancer Type Data base Literature cross ~20 biomarkers Preferred test Serum samples CRO confirms CRO performs 100 Rhythm identifies mining for check selected provider for each obtained for 100 preferred test case/100 control bes
Slide 15: Rhythm's 12 Month Focus
Rhythm’s 12 Month Focus ✓ FY’24 commercial sales – initially focused on addressable markets ✓ UK market launch: • Establishing KOLs • Developing partnerships with key labs for growth • Maximising sales revenue through the private market ✓ South African market strategy & entry: • Establishing a partn
Slide 16: Rhythm's 12 Month Focus
Rhythm’s 12 Month Focus ✓ USA market launch and strategy • Finalise an approach to market via a CLIA lab pathway • Partner with leading pathology / medical institutions to provide ease of market entry ✓ Australian market entry: • Regulatory approval into Australia • Ensure that regulatory approval i
Slide 17: Thank you and Questions
Thank you and Questions www.rhythmbio.com 17
Slide 18: References
References Slide 6 1. Xi Y, Xu P (2021), Global colorectal cancer burden in 2020 and projections to 2040, Translational Oncology, 14(10), 101174,doi:10.1016/j.tranon.2021.101174 Epub 2021 Jul 6 2. Center for Disease Control and Prevention (CDC). Colorectal cancer, available at: https://www.cdc.gov/c
Rhythm Biosciences — Investor Presentation (June 2023) on 6ix